OKYO Pharma CEO Interview to Air on Bloomberg TV
OKYO Pharma (NASDAQ: OKYO) announced that an interview with CEO Dr. Gary S. Jacob will air on Bloomberg TV's The RedChip Small Stocks, Big Money™ show on August 24, 2024, at 7 p.m. ET. The interview will provide a corporate update on OKYO's development of innovative therapies for Dry Eye Disease (DED) and Neuropathic Corneal Pain (NCP).
OKYO's lead candidate, OK-101, a lipid-conjugated chemerin peptide, has shown promising results in a recent Phase 2 trial for DED, demonstrating improvements in symptoms and signs within 15 days with a favorable safety profile. The company is also targeting NCP, an ocular condition without FDA-approved treatments. OKYO has patent protection through 2039 and an experienced management team with a track record of successful clinical development and FDA approvals.
OKYO Pharma (NASDAQ: OKYO) ha annunciato che un'intervista con il CEO Dr. Gary S. Jacob verrà trasmessa su Bloomberg TV nel programma The RedChip Small Stocks, Big Money™ il 24 agosto 2024, alle 19:00 ET. L'intervista offrirà un aggiornamento aziendale sullo sviluppo da parte di OKYO di terapie innovative per la malattia dell'occhio secco (DED) e il dolore corneale neuropatico (NCP).
Il principale candidato di OKYO, OK-101, un peptide chemerina coniugato a lipidi, ha mostrato risultati promettenti in un recente studio di Fase 2 per DED, dimostrando miglioramenti nei sintomi e nei segni entro 15 giorni con un profilo di sicurezza favorevole. L'azienda sta inoltre puntando su NCP, una condizione oculare senza trattamenti approvati dalla FDA. OKYO gode di protezione brevettuale fino al 2039 e dispone di un team di gestione esperto con una comprovata esperienza nello sviluppo clinico di successo e approvazioni dalla FDA.
OKYO Pharma (NASDAQ: OKYO) anunció que una entrevista con el CEO Dr. Gary S. Jacob se transmitirá en el programa The RedChip Small Stocks, Big Money™ de Bloomberg TV el 24 de agosto de 2024, a las 7 p.m. ET. La entrevista proporcionará una actualización corporativa sobre el desarrollo de OKYO de terapias innovadoras para la enfermedad del ojo seco (DED) y el dolor corneal neuropático (NCP).
El candidato principal de OKYO, OK-101, un péptido de quimerina conjugado a lípidos, ha mostrado resultados prometedores en un reciente ensayo de Fase 2 para DED, demostrando mejoras en los síntomas y signos en 15 días con un perfil de seguridad favorable. La empresa también está enfocándose en NCP, una condición ocular sin tratamientos aprobados por la FDA. OKYO tiene protección de patente hasta 2039 y un equipo de gestión experimentado con un historial de desarrollo clínico exitoso y aprobaciones de la FDA.
OKYO 파마(상장 코드: OKYO)는 CEO Dr. Gary S. Jacob과의 인터뷰가 2024년 8월 24일 오후 7시에 블룸버그 TV의 프로그램인 The RedChip Small Stocks, Big Money™에서 방송될 예정이라고 발표했습니다. 이 인터뷰는 OKYO의 안구건조증 (DED) 및 신경병성 각막 통증 (NCP)에 대한 혁신적인 치료법 개발에 대한 회사 업데이트를 제공합니다.
OKYO의 주요 후보인 OK-101은 지질 결합 화나민 펩타이드로, 최근 DED에 대한 2상 시험에서 증상과 징후 개선을 15일 이내에 입증하며 호의적인 안전성 프로필을 나타냈습니다. 회사는 또한 FDA 승인 치료법이 없는 안과적 상태인 NCP를 대상으로 하고 있습니다. OKYO는 2039년까지 특허 보호를 보유하고 있으며, 성공적인 임상 개발 및 FDA 승인 이력을 보유한 경험이 풍부한 경영진을 보유하고 있습니다.
OKYO Pharma (NASDAQ: OKYO) a annoncé qu'une interview avec le PDG Dr. Gary S. Jacob sera diffusée dans l'émission The RedChip Small Stocks, Big Money™ sur Bloomberg TV le 24 août 2024 à 19h00 ET. L'interview fournira une mise à jour d'entreprise sur le développement par OKYO de thérapies innovantes pour la sécheresse oculaire (DED) et la douleur cornéenne neuropathique (NCP).
Le principal candidat d'OKYO, OK-101, un peptide de chémérine conjugué à des lipides, a montré des résultats prometteurs lors d'un récent essai de Phase 2 pour DED, démontrant des améliorations des symptômes et des signes dans un délai de 15 jours avec un profil de sécurité favorable. L'entreprise cible également le NCP, une affection oculaire sans traitements approuvés par la FDA. OKYO bénéficie d'une protection par brevet jusqu'en 2039 et dispose d'une équipe de direction expérimentée ayant un bon bilan en matière de développement clinique et d'approbations de la FDA.
OKYO Pharma (NASDAQ: OKYO) hat bekannt gegeben, dass ein Interview mit CEO Dr. Gary S. Jacob am 24. August 2024 um 19 Uhr ET in der Bloomberg TV-Sendung The RedChip Small Stocks, Big Money™ ausgestrahlt wird. Das Interview wird ein Unternehmensupdate zu OKYOs Entwicklung innovativer Therapien für Trockenes Auge (DED) und neuropathische Hornhaut Schmerzen (NCP) bieten.
Der Hauptkandidat von OKYO, OK-101, ein lipidkonjugiertes Chemerin-Peptid, hat in einer kürzlich durchgeführten Phase-2-Studie für DED vielversprechende Ergebnisse gezeigt, mit Verbesserungen der Symptome und Zeichen innerhalb von 15 Tagen und einem günstigen Sicherheitsprofil. Das Unternehmen zielt auch auf NCP ab, eine okuläre Erkrankung ohne von der FDA zugelassene Behandlungen. OKYO hat Patentschutz bis 2039 und ein erfahrenes Management-Team, das auf eine erfolgreiche klinische Entwicklung und FDA-Zulassungen zurückblicken kann.
- Recent Phase 2 trial for DED showed notable improvements in symptoms and signs within 15 days
- OK-101 demonstrated a favorable safety profile with no drug-related serious adverse events
- OKYO has patent protection for its lead candidate through at least 2039
- The company is targeting NCP, an ocular condition with no FDA-approved treatments
- Management team has proven success in clinical development through FDA approval
- None.
LONDON and NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announced today an interview with its CEO, Dr. Gary S. Jacob will air on The RedChip Small Stocks, Big Money™ show on Bloomberg TV, this Saturday, August 24, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
In an exclusive interview, Gary S. Jacob, PhD, CEO of OKYO Pharma, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a corporate update. OKYO is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of Dry Eye Disease (DED) and Neuropathic Corneal Pain (NCP), two areas with significant unmet medical needs. Leveraging a unique lipid-conjugated chemerin peptide, OKYO’s lead candidate, OK-101, is designed to address inflammation and pain more effectively than current treatments. The recent Phase 2 trial for DED demonstrated notable improvements in both symptoms and signs within just 15 days, with a favorable safety profile and no drug-related serious adverse events. Moreover, OK-101 also offers a significant opportunity to treat the ocular disease called NCP, with no FDA approved drug to treat patients suffering from this acute, chronic, ocular condition. OKYO’s robust patent protection through at least 2039, plus an experienced management team, with proven success in clinical development through FDA approval, underscore its strong positioning for future growth in ophthalmology therapeutics.
A replay will be available in the Investor media section of the Company’s website https://okyopharma.com/media/
About OK-101
OK-101 is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response. OK-101 was developed using a membrane-anchored-peptide technology to produce a novel long-acting drug candidate for treating dry eye disease. OK-101 has been shown to produce anti-inflammatory and pain-reducing efficacy signals in mouse models of dry eye disease and corneal neuropathic pain (NCP), respectively, and is designed to combat washout through the inclusion of the lipid anchor built into the drug molecule to enhance the residence time of OK-101 within the ocular environment. OK-101 recently showed statistical significance in multiple endpoints in a recently completed Phase 2, multi-center, double-blind, placebo-controlled trial of OK-101 to treat DED.
About OKYO
OKYO Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of DED and NCP, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat inflammatory DED and ocular pain. In addition to the recently completed Phase 2 DED trial, OKYO also has plans underway for the opening of a Phase 2 trial for OK-101 to treat NCP in patients with this debilitating condition. For further information, please visit www.okyopharma.com.
Enquiries:
| OKYO Pharma Limited | Gary S. Jacob, Chief Executive Officer | 917-497-7560 |
| Business Development & Investor Relations | Paul Spencer | +44 (0)20 7495 2379 |
FAQ
When will OKYO Pharma's CEO interview air on Bloomberg TV?
What are the main therapeutic areas OKYO Pharma (OKYO) is focusing on?
What were the results of OKYO Pharma's (OKYO) recent Phase 2 trial for Dry Eye Disease?
How long does OKYO Pharma (OKYO) have patent protection for its lead candidate?
